[celticninja]

I can't see the list (from EU) but this is an example

https://www.theguardian.com/society/2021/jun/01/baby-boy-is-...

I am willing to bet that this is used to save more lives in the UK than the drug will in the US.

spinal muscular atrophy is the number 1 cause of child mortality in the UK, now any child with this disease can get the treatment. In the US people will still need to jump through hoops with their insurance company to get the treatment and there will be cases that go untreated because of the cost.

[1123581321]

Zolgensma is one on the list that was approved earlier in the US than in Europe, requiring parents to fundraise during the gap period. Regarding absolute numbers, there are more SMA cases in the US than the UK. This is due to the overall population difference as well as a larger number of disproportionately affected populations which contributes to a higher rate of incidence. Zolgensma is authorized for treatment and payment using a similar review process and set of criteria in both countries. This is the case for both private/employer insurance coverage and pediatric public health programs. So I would take that bet.

Generally speaking, the US insurance system handles catastrophically expensive cases well. It’s the smallish cases (broken legs, etc) that are burdensome as copays leave families on the hook for several hundred to a few thousand dollars after insurance pays its contribution.